Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial


The malaria vaccine RTS,S/AS01 is sustaining some efficacy up to seven years after vaccination, according to this study, which could potentially result in significant benefits to public health.

Content Information

Content Author: 
Halidou Tinto, Walter Otieno, Samwel Gesase, et al
Content Source: 
Lancet Infectious Diseases
Content Type: 
News